The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity

Stefano Camnasio, Alessia Delli Carri, Angelo Lombardo, Iwona Grad, Caterina Mariotti, Alessia Castucci, Björn Rozell, Pietro Lo Riso, Valentina Castiglioni, Chiara Zuccato, Christelle Rochon, Yasuhiro Takashima, Giuseppe Diaferia, Ida Biunno, Cinzia Gellera, Marisa Jaconi, Austin Smith, Outi Hovatta, Luigi Naldini, Stefano Di DonatoAnis Feki, Elena Cattaneo

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Neuronal disorders, like Huntington's disease (HD), are difficult to study, due to limited cell accessibility, late onset manifestations, and low availability of material. The establishment of an in vitro model that recapitulates features of the disease may help understanding the cellular and molecular events that trigger disease manifestations. Here, we describe the generation and characterization of a series of induced pluripotent stem (iPS) cells derived from patients with HD, including two rare homozygous genotypes and one heterozygous genotype. We used lentiviral technology to transfer key genes for inducing reprogramming. To confirm pluripotency and differentiation of iPS cells, we used PCR amplification and immunocytochemistry to measure the expression of marker genes in embryoid bodies and neurons. We also analyzed teratomas that formed in iPS cell-injected mice. We found that the length of the pathological CAG repeat did not increase during reprogramming, after long term growth in vitro, and after differentiation into neurons. In addition, we observed no differences between normal and mutant genotypes in reprogramming, growth rate, caspase activation or neuronal differentiation. However, we observed a significant increase in lysosomal activity in HD-iPS cells compared to control iPS cells, both during self-renewal and in iPS-derived neurons.In conclusion, we have established stable HD-iPS cell lines that can be used for investigating disease mechanisms that underlie HD. The CAG stability and lysosomal activity represent novel observations in HD-iPS cells. In the future, these cells may provide the basis for a powerful platform for drug screening and target identification in HD.

Original languageEnglish
Pages (from-to)41-51
Number of pages11
JournalNeurobiology of Disease
Volume46
Issue number1
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Induced Pluripotent Stem Cells
Huntington Disease
Cell Line
Mutation
Genotype
Neurons
Embryoid Bodies
Technology Transfer
Preclinical Drug Evaluations
Teratoma
Growth
Caspases
Immunohistochemistry
Gene Expression
Polymerase Chain Reaction
Genes

Keywords

  • Human induced pluripotent stem cells
  • Huntington's disease
  • Neuronal differentiation

ASJC Scopus subject areas

  • Neurology

Cite this

The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. / Camnasio, Stefano; Carri, Alessia Delli; Lombardo, Angelo; Grad, Iwona; Mariotti, Caterina; Castucci, Alessia; Rozell, Björn; Riso, Pietro Lo; Castiglioni, Valentina; Zuccato, Chiara; Rochon, Christelle; Takashima, Yasuhiro; Diaferia, Giuseppe; Biunno, Ida; Gellera, Cinzia; Jaconi, Marisa; Smith, Austin; Hovatta, Outi; Naldini, Luigi; Di Donato, Stefano; Feki, Anis; Cattaneo, Elena.

In: Neurobiology of Disease, Vol. 46, No. 1, 04.2012, p. 41-51.

Research output: Contribution to journalArticle

Camnasio, S, Carri, AD, Lombardo, A, Grad, I, Mariotti, C, Castucci, A, Rozell, B, Riso, PL, Castiglioni, V, Zuccato, C, Rochon, C, Takashima, Y, Diaferia, G, Biunno, I, Gellera, C, Jaconi, M, Smith, A, Hovatta, O, Naldini, L, Di Donato, S, Feki, A & Cattaneo, E 2012, 'The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity', Neurobiology of Disease, vol. 46, no. 1, pp. 41-51. https://doi.org/10.1016/j.nbd.2011.12.042
Camnasio, Stefano ; Carri, Alessia Delli ; Lombardo, Angelo ; Grad, Iwona ; Mariotti, Caterina ; Castucci, Alessia ; Rozell, Björn ; Riso, Pietro Lo ; Castiglioni, Valentina ; Zuccato, Chiara ; Rochon, Christelle ; Takashima, Yasuhiro ; Diaferia, Giuseppe ; Biunno, Ida ; Gellera, Cinzia ; Jaconi, Marisa ; Smith, Austin ; Hovatta, Outi ; Naldini, Luigi ; Di Donato, Stefano ; Feki, Anis ; Cattaneo, Elena. / The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. In: Neurobiology of Disease. 2012 ; Vol. 46, No. 1. pp. 41-51.
@article{bdfa895460fb4992a0c9fba72228aa11,
title = "The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity",
abstract = "Neuronal disorders, like Huntington's disease (HD), are difficult to study, due to limited cell accessibility, late onset manifestations, and low availability of material. The establishment of an in vitro model that recapitulates features of the disease may help understanding the cellular and molecular events that trigger disease manifestations. Here, we describe the generation and characterization of a series of induced pluripotent stem (iPS) cells derived from patients with HD, including two rare homozygous genotypes and one heterozygous genotype. We used lentiviral technology to transfer key genes for inducing reprogramming. To confirm pluripotency and differentiation of iPS cells, we used PCR amplification and immunocytochemistry to measure the expression of marker genes in embryoid bodies and neurons. We also analyzed teratomas that formed in iPS cell-injected mice. We found that the length of the pathological CAG repeat did not increase during reprogramming, after long term growth in vitro, and after differentiation into neurons. In addition, we observed no differences between normal and mutant genotypes in reprogramming, growth rate, caspase activation or neuronal differentiation. However, we observed a significant increase in lysosomal activity in HD-iPS cells compared to control iPS cells, both during self-renewal and in iPS-derived neurons.In conclusion, we have established stable HD-iPS cell lines that can be used for investigating disease mechanisms that underlie HD. The CAG stability and lysosomal activity represent novel observations in HD-iPS cells. In the future, these cells may provide the basis for a powerful platform for drug screening and target identification in HD.",
keywords = "Human induced pluripotent stem cells, Huntington's disease, Neuronal differentiation",
author = "Stefano Camnasio and Carri, {Alessia Delli} and Angelo Lombardo and Iwona Grad and Caterina Mariotti and Alessia Castucci and Bj{\"o}rn Rozell and Riso, {Pietro Lo} and Valentina Castiglioni and Chiara Zuccato and Christelle Rochon and Yasuhiro Takashima and Giuseppe Diaferia and Ida Biunno and Cinzia Gellera and Marisa Jaconi and Austin Smith and Outi Hovatta and Luigi Naldini and {Di Donato}, Stefano and Anis Feki and Elena Cattaneo",
year = "2012",
month = "4",
doi = "10.1016/j.nbd.2011.12.042",
language = "English",
volume = "46",
pages = "41--51",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity

AU - Camnasio, Stefano

AU - Carri, Alessia Delli

AU - Lombardo, Angelo

AU - Grad, Iwona

AU - Mariotti, Caterina

AU - Castucci, Alessia

AU - Rozell, Björn

AU - Riso, Pietro Lo

AU - Castiglioni, Valentina

AU - Zuccato, Chiara

AU - Rochon, Christelle

AU - Takashima, Yasuhiro

AU - Diaferia, Giuseppe

AU - Biunno, Ida

AU - Gellera, Cinzia

AU - Jaconi, Marisa

AU - Smith, Austin

AU - Hovatta, Outi

AU - Naldini, Luigi

AU - Di Donato, Stefano

AU - Feki, Anis

AU - Cattaneo, Elena

PY - 2012/4

Y1 - 2012/4

N2 - Neuronal disorders, like Huntington's disease (HD), are difficult to study, due to limited cell accessibility, late onset manifestations, and low availability of material. The establishment of an in vitro model that recapitulates features of the disease may help understanding the cellular and molecular events that trigger disease manifestations. Here, we describe the generation and characterization of a series of induced pluripotent stem (iPS) cells derived from patients with HD, including two rare homozygous genotypes and one heterozygous genotype. We used lentiviral technology to transfer key genes for inducing reprogramming. To confirm pluripotency and differentiation of iPS cells, we used PCR amplification and immunocytochemistry to measure the expression of marker genes in embryoid bodies and neurons. We also analyzed teratomas that formed in iPS cell-injected mice. We found that the length of the pathological CAG repeat did not increase during reprogramming, after long term growth in vitro, and after differentiation into neurons. In addition, we observed no differences between normal and mutant genotypes in reprogramming, growth rate, caspase activation or neuronal differentiation. However, we observed a significant increase in lysosomal activity in HD-iPS cells compared to control iPS cells, both during self-renewal and in iPS-derived neurons.In conclusion, we have established stable HD-iPS cell lines that can be used for investigating disease mechanisms that underlie HD. The CAG stability and lysosomal activity represent novel observations in HD-iPS cells. In the future, these cells may provide the basis for a powerful platform for drug screening and target identification in HD.

AB - Neuronal disorders, like Huntington's disease (HD), are difficult to study, due to limited cell accessibility, late onset manifestations, and low availability of material. The establishment of an in vitro model that recapitulates features of the disease may help understanding the cellular and molecular events that trigger disease manifestations. Here, we describe the generation and characterization of a series of induced pluripotent stem (iPS) cells derived from patients with HD, including two rare homozygous genotypes and one heterozygous genotype. We used lentiviral technology to transfer key genes for inducing reprogramming. To confirm pluripotency and differentiation of iPS cells, we used PCR amplification and immunocytochemistry to measure the expression of marker genes in embryoid bodies and neurons. We also analyzed teratomas that formed in iPS cell-injected mice. We found that the length of the pathological CAG repeat did not increase during reprogramming, after long term growth in vitro, and after differentiation into neurons. In addition, we observed no differences between normal and mutant genotypes in reprogramming, growth rate, caspase activation or neuronal differentiation. However, we observed a significant increase in lysosomal activity in HD-iPS cells compared to control iPS cells, both during self-renewal and in iPS-derived neurons.In conclusion, we have established stable HD-iPS cell lines that can be used for investigating disease mechanisms that underlie HD. The CAG stability and lysosomal activity represent novel observations in HD-iPS cells. In the future, these cells may provide the basis for a powerful platform for drug screening and target identification in HD.

KW - Human induced pluripotent stem cells

KW - Huntington's disease

KW - Neuronal differentiation

UR - http://www.scopus.com/inward/record.url?scp=84863230167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863230167&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2011.12.042

DO - 10.1016/j.nbd.2011.12.042

M3 - Article

C2 - 22405424

AN - SCOPUS:84863230167

VL - 46

SP - 41

EP - 51

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - 1

ER -